title: Rapid drug susceptibility testing with a molecular beacon assay is associated with earlier diagnosis and treatment of multidrug-resistant tuberculosis in California.
abstract: To assess the clinical impact of a molecular beacon (MB) assay that detects multidrug-resistant tuberculosis (MDR TB), we retrospectively reviewed records of 127 MDR TB patients with and without MB testing between 2004 and 2007. Use of the MB assay reduced the time to detection and treatment of MDR TB.
authors: Division of Pediatric Infectious Diseases, Mayo Clinic, Rochester, MN 55905, USA. Banerjee.ritu@mayo.edu
authors: Ritu
authors: R
authors: Banerjee
authors: Jennifer
authors: J
authors: Allen
authors: S-Y Grace
authors: SY
authors: Lin
authors: Janice
authors: J
authors: Westenhouse
authors: Ed
authors: E
authors: Desmond
authors: Gisela F
authors: GF
authors: Schecter
authors: Cheryl
authors: C
authors: Scott
authors: Ann
authors: A
authors: Raftery
authors: Sundari
authors: S
authors: Mase
authors: James P
authors: JP
authors: Watt
authors: Jennifer
authors: J
authors: Flood
mesh_terms: D000328:Adult; D000995:Antitubercular Agents / Q000494:pharmacology / Q000627:therapeutic use; D002140:California; D042241:Early Diagnosis; D005260:Female; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests / Q000379:methods; D008875:Middle Aged; D025202:Molecular Diagnostic Techniques / Q000379:methods*; D009169:Mycobacterium tuberculosis / Q000187:drug effects* / Q000235:genetics / Q000302:isolation & purification*; D012189:Retrospective Studies; D013997:Time Factors; D018088:Tuberculosis, Multidrug-Resistant / Q000175:diagnosis* / Q000382:microbiology*
chemical_list: D000995:Antitubercular Agents